{"id":"https://openalex.org/W1977511181","doi":"https://doi.org/10.4088/jcp.08m04772gre","title":"Olanzapine/Fluoxetine Combination for the Treatment of Mixed Depression in Bipolar I Disorder","display_name":"Olanzapine/Fluoxetine Combination for the Treatment of Mixed Depression in Bipolar I Disorder","publication_year":2009,"publication_date":"2009-10-15","ids":{"openalex":"https://openalex.org/W1977511181","doi":"https://doi.org/10.4088/jcp.08m04772gre","mag":"1977511181","pmid":"https://pubmed.ncbi.nlm.nih.gov/19906346"},"language":"en","primary_location":{"id":"doi:10.4088/jcp.08m04772gre","doi":"https://doi.org/10.4088/jcp.08m04772gre","is_oa":false,"landing_page_url":"https://doi.org/10.4088/jcp.08m04772gre","pdf_url":null,"source":{"id":"https://openalex.org/S17992710","display_name":"The Journal of Clinical Psychiatry","issn_l":"0160-6689","issn":["0160-6689","1534-8628","1555-2101"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4322614534","host_organization_name":"Physicians Postgraduate Press, Inc.","host_organization_lineage":["https://openalex.org/P4322614534"],"host_organization_lineage_names":["Physicians Postgraduate Press, Inc."],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Clinical Psychiatry","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5038773427","display_name":"Franco Benazzi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Franco Benazzi","raw_affiliation_strings":["Hecker Psychiatry Research Center, Forli, Italy. FrancoBenazzi@FBenazzi.it","Hecker Psychiatry Research Center, Forli, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hecker Psychiatry Research Center, Forli, Italy. FrancoBenazzi@FBenazzi.it","institution_ids":[]},{"raw_affiliation_string":"Hecker Psychiatry Research Center, Forli, Italy","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Michael Berk","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I165779595","display_name":"The University of Melbourne","ror":"https://ror.org/01ej9dk98","country_code":"AU","type":"education","lineage":["https://openalex.org/I165779595"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Michael Berk","raw_affiliation_strings":["University of Melbourne"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Melbourne","institution_ids":["https://openalex.org/I165779595"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029433360","display_name":"Mark A. Frye","orcid":"https://orcid.org/0000-0001-6997-4215","observed_orcids":["https://orcid.org/0000-0001-6997-4215"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark A. Frye","raw_affiliation_strings":["Psychiatry and Psychology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Psychiatry and Psychology","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100392053","display_name":"Wei Wang","orcid":"https://orcid.org/0000-0002-6822-8162","observed_orcids":["https://orcid.org/0000-0002-6822-8162"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wei Wang","raw_affiliation_strings":["Eli-Lilly"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli-Lilly","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051261665","display_name":"Alessandra Barraco","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164813","display_name":"Eli Lilly (Italy)","ror":"https://ror.org/05d0e9y67","country_code":"IT","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210164813"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Alessandra Barraco","raw_affiliation_strings":["Ely Lilly Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ely Lilly Italy","institution_ids":["https://openalex.org/I4210164813"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5007497235","display_name":"Mauricio F. Tohen","orcid":"https://orcid.org/0000-0001-8049-4351","observed_orcids":["https://orcid.org/0000-0001-8049-4351"]},"institutions":[{"id":"https://openalex.org/I45438204","display_name":"The University of Texas at San Antonio","ror":"https://ror.org/01kd65564","country_code":"US","type":"education","lineage":["https://openalex.org/I45438204"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mauricio Tohen","raw_affiliation_strings":["University of Texas at San Antonio"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas at San Antonio","institution_ids":["https://openalex.org/I45438204"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5038773427"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.4957,"has_fulltext":false,"cited_by_count":65,"citation_normalized_percentile":{"value":0.88216254,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"70","issue":"10","first_page":"1424","last_page":"1431"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10854","display_name":"Bipolar Disorder and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10854","display_name":"Bipolar Disorder and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mixed-depression","display_name":"mixed depression","score":0.781000018119812},{"id":"https://openalex.org/keywords/bipolar-i-disorder","display_name":"bipolar I disorder","score":0.9480000138282776},{"id":"https://openalex.org/keywords/olanzapine","display_name":"olanzapine","score":0.8939999938011169},{"id":"https://openalex.org/keywords/fluoxetine","display_name":"fluoxetine","score":0.9829999804496765},{"id":"https://openalex.org/keywords/olanzapine-fluoxetine-combination","display_name":"olanzapine-fluoxetine combination","score":0.9539999961853027},{"id":"https://openalex.org/keywords/bipolar-depression","display_name":"bipolar depression","score":0.5929999947547913},{"id":"https://openalex.org/keywords/combination-antidepressant-therapy","display_name":"antidepressant combination therapy","score":0.5929999947547913},{"id":"https://openalex.org/keywords/antipsychotic-drugs","display_name":"antipsychotic drugs","score":0.7099999785423279},{"id":"https://openalex.org/keywords/treatment-response","display_name":"treatment response","score":0.4659999907016754},{"id":"https://openalex.org/keywords/irritability","display_name":"irritability","score":0.5730000138282776},{"id":"https://openalex.org/keywords/sleep-reduction","display_name":"sleep reduction","score":0.5540000200271606},{"id":"https://openalex.org/keywords/young-mania-rating-scale","display_name":"Young Mania Rating Scale","score":0.7559999823570251},{"id":"https://openalex.org/keywords/montgomery-asberg-depression-rating-scale","display_name":"Montgomery-Asberg Depression Rating Scale","score":0.9559999704360962},{"id":"https://openalex.org/keywords/post-hoc-analysis","display_name":"post hoc analysis","score":0.6549999713897705},{"id":"https://openalex.org/keywords/mood-stabilizers","display_name":"mood stabilizers","score":0.4779999852180481},{"id":"https://openalex.org/keywords/antidepressants","display_name":"antidepressants","score":0.32499998807907104}],"concepts":[{"id":"https://openalex.org/C2778567577","wikidata":"https://www.wikidata.org/wiki/Q188611","display_name":"Hypomania","level":5,"score":0.880511999130249},{"id":"https://openalex.org/C2776809841","wikidata":"https://www.wikidata.org/wiki/Q185935","display_name":"Mania","level":4,"score":0.7623614072799683},{"id":"https://openalex.org/C2776619155","wikidata":"https://www.wikidata.org/wiki/Q201872","display_name":"Olanzapine","level":3,"score":0.7344801425933838},{"id":"https://openalex.org/C2777089681","wikidata":"https://www.wikidata.org/wiki/Q4340609","display_name":"Young Mania Rating Scale","level":5,"score":0.722907543182373},{"id":"https://openalex.org/C2776174506","wikidata":"https://www.wikidata.org/wiki/Q131755","display_name":"Bipolar disorder","level":3,"score":0.6831167340278625},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.6139015555381775},{"id":"https://openalex.org/C2775972397","wikidata":"https://www.wikidata.org/wiki/Q3577449","display_name":"Montgomery\u2013\u00c5sberg Depression Rating Scale","level":4,"score":0.5705603361129761},{"id":"https://openalex.org/C2776592573","wikidata":"https://www.wikidata.org/wiki/Q4086956","display_name":"Bipolar II disorder","level":4,"score":0.562833845615387},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.5512619018554688},{"id":"https://openalex.org/C2776134451","wikidata":"https://www.wikidata.org/wiki/Q422244","display_name":"Fluoxetine","level":4,"score":0.5328013896942139},{"id":"https://openalex.org/C2776921671","wikidata":"https://www.wikidata.org/wiki/Q758295","display_name":"Atypical antipsychotic","level":4,"score":0.48960787057876587},{"id":"https://openalex.org/C2777270317","wikidata":"https://www.wikidata.org/wiki/Q205517","display_name":"Ziprasidone","level":4,"score":0.453810453414917},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.45046350359916687},{"id":"https://openalex.org/C2778609679","wikidata":"https://www.wikidata.org/wiki/Q4915474","display_name":"Bipolar I disorder","level":5,"score":0.44449931383132935},{"id":"https://openalex.org/C2776867660","wikidata":"https://www.wikidata.org/wiki/Q1814941","display_name":"Depression (economics)","level":2,"score":0.41856902837753296},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.38030171394348145},{"id":"https://openalex.org/C2780051608","wikidata":"https://www.wikidata.org/wiki/Q42844","display_name":"Major depressive disorder","level":3,"score":0.37198373675346375},{"id":"https://openalex.org/C2780733359","wikidata":"https://www.wikidata.org/wiki/Q331769","display_name":"Mood","level":2,"score":0.3217977285385132},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3108847737312317},{"id":"https://openalex.org/C2780494398","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic","level":3,"score":0.2842891216278076},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.18083181977272034},{"id":"https://openalex.org/C139719470","wikidata":"https://www.wikidata.org/wiki/Q39680","display_name":"Macroeconomics","level":1,"score":0.0},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.0},{"id":"https://openalex.org/C2775864247","wikidata":"https://www.wikidata.org/wiki/Q167934","display_name":"Serotonin","level":3,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000077152","descriptor_name":"Olanzapine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001569","descriptor_name":"Benzodiazepines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001714","descriptor_name":"Bipolar Disorder","qualifier_ui":"Q000145","qualifier_name":"classification","is_major_topic":false},{"descriptor_ui":"D001714","descriptor_name":"Bipolar Disorder","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001714","descriptor_name":"Bipolar Disorder","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D001714","descriptor_name":"Bipolar Disorder","qualifier_ui":"Q000523","qualifier_name":"psychology","is_major_topic":false},{"descriptor_ui":"D003865","descriptor_name":"Major Depressive Disorder","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003865","descriptor_name":"Major Depressive Disorder","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D003865","descriptor_name":"Major Depressive Disorder","qualifier_ui":"Q000523","qualifier_name":"psychology","is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005473","descriptor_name":"Fluoxetine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010919","descriptor_name":"Placebos","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015897","descriptor_name":"Comorbidity","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018687","descriptor_name":"Antidepressive Agents, Second-Generation","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D018967","descriptor_name":"Risperidone","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.4088/jcp.08m04772gre","doi":"https://doi.org/10.4088/jcp.08m04772gre","is_oa":false,"landing_page_url":"https://doi.org/10.4088/jcp.08m04772gre","pdf_url":null,"source":{"id":"https://openalex.org/S17992710","display_name":"The Journal of Clinical Psychiatry","issn_l":"0160-6689","issn":["0160-6689","1534-8628","1555-2101"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4322614534","host_organization_name":"Physicians Postgraduate Press, Inc.","host_organization_lineage":["https://openalex.org/P4322614534"],"host_organization_lineage_names":["Physicians Postgraduate Press, Inc."],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Clinical Psychiatry","raw_type":"journal-article"},{"id":"pmid:19906346","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19906346","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of clinical psychiatry","raw_type":"Comparative Study"},{"id":"pmh:oai:figshare.com:article/20920930","doi":null,"is_oa":false,"landing_page_url":"https://figshare.com/articles/journal_contribution/Olanzapine_fluoxetine_combination_for_the_treatment_of_mixed_depression_in_bipolar_I_disorder_a_post_hoc_analysis/20920930","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Text"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9907000064849854}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2111355579","https://openalex.org/W2006178344","https://openalex.org/W1988187423","https://openalex.org/W1974910824","https://openalex.org/W2142581464","https://openalex.org/W2136733340","https://openalex.org/W4230643114","https://openalex.org/W2108593299","https://openalex.org/W2118660566","https://openalex.org/W2045545621"],"abstract_inverted_index":{"OBJECTIVE:":[0],"Mixed":[1,140],"depression":[2,7,81,107,141,214,243,260,265,317,358,421,426,448,551,590],"(ie,":[3,159],"co-occurrence":[4,146],"of":[5,15,26,34,44,47,59,72,77,113,147,212,241,313,356,365,389,415,433,439,444,511,519,523,532,536,546,553,556],"syndromal":[6],"and":[8,37,41,51,126,152,191,226,251,378,404,462,564,584],"subsyndromal":[9],"mania/hypomania)":[10],"is":[11,21],"a":[12,68,110,148,179,203,371,528,533,560,565,594],"common":[13],"variant":[14],"bipolar":[16,60,79,504,549,588],"depression.":[17,63,507],"However,":[18],"its":[19],"treatment":[20,58,131,360,435,502],"much":[22],"understudied.":[23],"The":[24,235,387,413,437],"aim":[25],"the":[27,32,35,42,45,57,114,119,133,145,218,223,229,267,270,283,296,311,319,376,384,392,395,400,406,434,442,450,453,458,464,509,524,539,543,554],"study":[28,540],"was":[29,108,142,176,200,215,349,513],"to":[30,124,130,137,198,571,574],"assess":[31],"efficacy":[33,43,510,545,583],"antipsychotic":[36],"mood-stabilizing":[38,595],"agent":[39,596],"olanzapine":[40,52,88,224,284,339,377,401,459],"combination":[46,497],"an":[48,73,500,579],"antidepressant":[49,580],"(fluoxetine)":[50,581],"(olanzapine/fluoxetine":[53,96],"combination;":[54],"OFC)":[55],"for":[56,248,503],"I":[61,80,505],"mixed":[62,106,213,242,264,316,357,420,447,506,550,589],"METHOD:":[64],"We":[65],"carried":[66],"out":[67],"post":[69],"hoc":[70],"analysis":[71],"8-week,":[74],"double-blind":[75,115],"trial":[76,120],"adult":[78],"treated":[82],"with":[83,258,263,315,419,424,446,593],"placebo":[84,230,297,379,407,465,477,486],"(n":[85],"=":[86,92,103,155,162,173,182,208,233,277,290,303,325,334,343,411,472,481,490],"355),":[87],"(5-20":[89],"mg/d;":[90,101],"n":[91,102],"351),":[93],"or":[94,154,161,172,181,207],"OFC":[95,219,271,321,330,385,396,454,512,547],"doses:":[97],"6/25,":[98],"6/50,":[99],"12/50":[100],"82).":[104],"Studying":[105],"not":[109,382,428,514,586],"previous":[111],"goal":[112],"trial.":[116],"Subjects":[117],"in":[118,185,217,222,228,256,269,282,295,310,375,383,394,399,405,417,441,452,457,463,530,548],"were":[121,127,244,266,318,391,427,449],"diagnosed":[122],"according":[123],"DSM-IV":[125],"randomly":[128],"assigned":[129],"during":[132],"period":[134],"June":[135],"2000":[136],"December":[138],"2001.":[139],"defined":[143,177,201],"as":[144,178,202],"major":[149],"depressive":[150],"episode":[151],">":[153,160,171,180,206],"2":[156,163,193],"manic/hypomanic":[157,195,354,368,558],"symptoms":[158,240,369],"Young":[164],"Mania":[165],"Rating":[166,188],"Scale":[167,189],"[YMRS]":[168],"items":[169],"scoring":[170],"2).":[174],"Response":[175,254,308],"50%":[183],"reduction":[184],"Montgomery-Asberg":[186],"Depression":[187],"score":[190,205],"<":[192],"concurrent":[194,367,557],"symptoms.":[196],"Switching":[197],"mania/hypomania":[199],"YMRS":[204],"15.":[209],"RESULTS:":[210],"Frequency":[211],"45.1%":[216],"arm,":[220,225,272,285,298,397,402,408,455,460,466],"49.3%":[221],"46.8%":[227],"arm":[231],"(P":[232,410],".705).":[234],"most":[236],"frequent":[237],"manic/":[238],"hypomanic":[239],"irritability,":[245],"reduced":[246],"need":[247],"sleep,":[249],"talkativeness,":[250],"racing":[252],"thoughts.":[253],"rates":[255,309,388,414,438],"patients":[257,262,314,418,423,445],"nonmixed":[259,425],"versus":[261,274,287,300,322,331,340,422],"following:":[268,320,393,451],"48.9%":[273],"43.2%":[275],"(OR":[276,289,302],"1.24;":[278],"95%":[279,292,305,474,483,492,525],"CI,":[280,293,306,328,337,346,475,484,493],"0.51-2.98);":[281],"39.9%":[286],"26.6%":[288],"1.84;":[291],"1.17-2.90);":[294],"27.5%":[299],"16.3%":[301],"1.94;":[304],"1.15-3.28).":[307],"samples":[312,443],"olanzapine,":[323,520],"OR":[324,333,342,471,480,489],"2.00":[326],"(95%":[327,336,345],"0.96-4.19);":[329],"placebo,":[332,341],"3.91":[335],"1.80-8.49);":[338],"1.95":[344],"1.14-3.34).":[347],"It":[348],"found":[350],"that":[351,518],"no":[352],"baseline":[353,366],"symptom":[355],"predicted":[359,370],"response.":[361],"A":[362],"higher":[363],"number":[364,555],"lower":[372,561],"response":[373],"rate":[374,569],"arms,":[380],"but":[381,521],"arm.":[386],"switching":[390,568],"8.5%;":[398],"6.8%;":[403],"7.9%":[409],".808).":[412],"dropouts":[416,440],"significantly":[429,515],"different":[430,516],"within":[431],"any":[432],"arms.":[436],"29.7%;":[456],"53.8%;":[461],"59.6%":[467],"(olanzapine":[468],"vs":[469,478,487],"OFC:":[470,479],"2.66;":[473],"1.23-5.75;":[476],"3.48;":[482],"1.61-7.54;":[485],"olanzapine:":[488],"1.30;":[491],"0.84-2.01).":[494],"CONCLUSION:":[495],"Olanzapine/fluoxetine":[496],"may":[498],"be":[499],"effective":[501],"Statistically,":[508],"from":[517],"inspection":[522],"CI":[526],"showed":[527,582],"trend":[529],"favor":[531],"possible":[534],"superiority":[535],"OFC.":[537],"Supporting":[538],"findings":[541],"are":[542],"similar":[544],"independent":[552],"symptoms,":[559],"dropout":[562],"rate,":[563],"similarly":[566],"low":[567],"compared":[570],"olanzapine.":[572],"Contrary":[573],"other":[575],"current":[576],"limited":[577],"evidence,":[578],"did":[585],"worsen":[587],"if":[591],"combined":[592],"(olanzapine).":[597]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":2},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":6},{"year":2016,"cited_by_count":8},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":5},{"year":2013,"cited_by_count":7},{"year":2012,"cited_by_count":5}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}